These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 18846053)

  • 1. CD20 blockers eye crowded rheumatology market.
    Mack GS
    Nat Biotechnol; 2008 Oct; 26(10):1053-4. PubMed ID: 18846053
    [No Abstract]   [Full Text] [Related]  

  • 2. Tysabri back on market.
    Sheridan C
    Nat Biotechnol; 2006 Aug; 24(8):874. PubMed ID: 16900111
    [No Abstract]   [Full Text] [Related]  

  • 3. GlaxoSmithKline cancer drug threatens Herceptin market.
    Waltz E
    Nat Biotechnol; 2005 Dec; 23(12):1453-4. PubMed ID: 16333273
    [No Abstract]   [Full Text] [Related]  

  • 4. Small-area variations in sales of TNF inhibitors in Sweden between 2000 and 2009: comments on the article by M Neovius et al.
    Ohlsson H; Merlo J
    Scand J Rheumatol; 2011 May; 40(3):243-4. PubMed ID: 21529245
    [No Abstract]   [Full Text] [Related]  

  • 5. Market watch: Upcoming catalysts in Q3 2014.
    Haggerty R
    Nat Rev Drug Discov; 2014 Jul; 13(7):486. PubMed ID: 24981351
    [No Abstract]   [Full Text] [Related]  

  • 6. A change in the market--investing in diagnostics.
    Batchelder K; Miller P
    Nat Biotechnol; 2006 Aug; 24(8):922-6. PubMed ID: 16900131
    [No Abstract]   [Full Text] [Related]  

  • 7. 'Biosimilar' drugs poised to penetrate market.
    Ledford H
    Nature; 2010 Nov; 468(7320):18-9. PubMed ID: 21048737
    [No Abstract]   [Full Text] [Related]  

  • 8. Biotech jostles with pharma for slice of HIV market.
    Katsnelson A
    Nat Biotechnol; 2006 Jan; 24(1):3-4. PubMed ID: 16404375
    [No Abstract]   [Full Text] [Related]  

  • 9. The pitfalls in the development of biologic therapy.
    Maini RN; Feldmann M
    Nat Clin Pract Rheumatol; 2007 Jan; 3(1):1. PubMed ID: 17202998
    [No Abstract]   [Full Text] [Related]  

  • 10. The biotech drug market.
    Lawrence S
    Nat Biotechnol; 2004 Dec; 22(12):1496. PubMed ID: 15583645
    [No Abstract]   [Full Text] [Related]  

  • 11. Designs that enrich lives.
    Link A; Stark H
    Arch Pharm (Weinheim); 2007 Oct; 340(10):509-10. PubMed ID: 17912676
    [No Abstract]   [Full Text] [Related]  

  • 12. Deal watch : BMS acquires rights for IL-6 inhibitor.
    Nat Rev Drug Discov; 2010 Jan; 9(1):10. PubMed ID: 20043020
    [No Abstract]   [Full Text] [Related]  

  • 13. Deconstructing Myogen's market cap.
    Ransom J
    Nat Biotechnol; 2006 Mar; 24(3):227-8. PubMed ID: 16525363
    [No Abstract]   [Full Text] [Related]  

  • 14. Market watch: upcoming market catalysts in Q3 2012.
    Jeng R
    Nat Rev Drug Discov; 2012 Jun; 11(7):508. PubMed ID: 22743969
    [No Abstract]   [Full Text] [Related]  

  • 15. Therapeutic B cell depletion and regeneration in rheumatoid arthritis: emerging patterns and paradigms.
    Silverman GJ
    Arthritis Rheum; 2006 Aug; 54(8):2356-67. PubMed ID: 16868991
    [No Abstract]   [Full Text] [Related]  

  • 16. Market watch: Biopharma deal-making in 2014: a record year for M&A value.
    Micklus A; Muntner S
    Nat Rev Drug Discov; 2015 Feb; 14(2):84-5. PubMed ID: 25633786
    [No Abstract]   [Full Text] [Related]  

  • 17. [The B-cell scrutinized].
    Krankenpfl J; 2005; 43(7-10):220-1. PubMed ID: 16515292
    [No Abstract]   [Full Text] [Related]  

  • 18. Small molecule challenges dominance of TNF-alpha inhibitors.
    Sheridan C
    Nat Biotechnol; 2008 Feb; 26(2):143-4. PubMed ID: 18259158
    [No Abstract]   [Full Text] [Related]  

  • 19. The long and winding road.
    Nat Rev Drug Discov; 2005 Jun; 4(6):443. PubMed ID: 15959946
    [No Abstract]   [Full Text] [Related]  

  • 20. Can 'double blockbuster' strengthen Amgen's backbone?
    Sheridan C
    Nat Biotechnol; 2008 Apr; 26(4):361-3. PubMed ID: 18391999
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.